Imugene (IMU) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Imugene Limited Successfully Passes All Resolutions at Extraordinary General MeetingJanuary 21 at 10:06 PM | tipranks.com3 ASX All Ords shares leading the charge in 2025January 10, 2025 | msn.comImugene Limited Announces New Securities Quotation on ASXJanuary 10, 2025 | tipranks.comImugene Secures $11.7m R&D Tax Refund to Boost Cancer Therapy DevelopmentJanuary 9, 2025 | tipranks.comImugene doses first Australian subject in trial of B-cell lymphoma drug candidateJanuary 3, 2025 | msn.comWhy Cettire, Gold Road, Imugene, and Paladin Energy shares are racing higherJanuary 3, 2025 | msn.comFirst Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma careJanuary 3, 2025 | msn.comImugene doses first Australian patient in Phase 1b azer-cel clinical trialJanuary 2, 2025 | au.investing.comImugene’s Australian Trial for Innovative Cancer Therapy BeginsJanuary 2, 2025 | tipranks.comASX Penny Stocks To Watch In January 2025January 1, 2025 | finance.yahoo.comImugene Secures A$46 Million for Clinical TrialsDecember 23, 2024 | markets.businessinsider.comImugene’s Azer-cel to be Featured at Major ConferenceDecember 19, 2024 | tipranks.comImugene Limited Secures $11 Million R&D Tax RefundDecember 18, 2024 | tipranks.com6 ASX shares down 50%+ in 2024. Are they cheap?December 3, 2024 | msn.comImugene Limited Updates and Focus on Cancer TherapiesNovember 21, 2024 | markets.businessinsider.comImugene Limited Announces Director Change and Stock HoldingsNovember 21, 2024 | markets.businessinsider.comImugene Limited: Leading Innovation in Cancer TreatmentNovember 14, 2024 | markets.businessinsider.comImugene Limited Advances Amidst AGM Vote ChallengesNovember 14, 2024 | markets.businessinsider.comASX Market Update: Index retreats as Chinese stimulus disappoints | November 11, 2024November 11, 2024 | msn.comImugene stocks well placed to grow with clinical progress on azer-cel CAR T-cell therapy and strong cash position, say analystsNovember 11, 2024 | au.investing.comImugene Limited Begins Innovative Cancer TrialNovember 11, 2024 | markets.businessinsider.comImugene Launches Phase 1b Trial in AustraliaNovember 8, 2024 | markets.businessinsider.comImugene kicks off Australian trial for blood cancer treatmentNovember 8, 2024 | msn.comROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsightNovember 6, 2024 | finance.yahoo.comImugene Achieves Milestone in Cancer Treatment TrialNovember 5, 2024 | markets.businessinsider.comWhy Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higherNovember 5, 2024 | msn.comThe Woolworths share price just hit a 52-week low: Is it a buy?November 3, 2024 | msn.com2 All Ords ASX healthcare shares making BIG moves on quarterly updatesOctober 31, 2024 | msn.comAdvanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersOctober 25, 2024 | theglobeandmail.comChartWatch ASX Scans: CAR Group, Clarity Pharmaceuticals, EBOS Group, Nick Scali, Nuix, Regis Resources, Sonic HealthcareSeptember 22, 2024 | msn.comAussie shares unchanged with all eyes on US rates callSeptember 18, 2024 | msn.comImugene Ltd Azer-cel Trial Update TranscriptSeptember 14, 2024 | gurufocus.comPrecision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel DealSeptember 3, 2024 | tmcnet.comThree Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)September 3, 2024 | finance.yahoo.comAust shares dip as REA Group mulls big takeover offerSeptember 3, 2024 | msn.comAustralian Market Modestly LowerSeptember 2, 2024 | markets.businessinsider.comStellar Resources confirms robust Heemskirk Tin Project with updated scoping studySeptember 2, 2024 | proactiveinvestors.comWhy this ASX All Ords stock is soaring 30% on MondaySeptember 2, 2024 | fool.com.auWhy Appen, Cettire, DroneShield, and Imugene shares are racing higherSeptember 2, 2024 | msn.comASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pcSeptember 2, 2024 | msn.comALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future Projections | DelveInsightAugust 30, 2024 | finance.yahoo.comImugene Ltd (IMU)August 30, 2024 | investing.comDelveInsight Business Research, LLP: Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsightAugust 22, 2024 | finanznachrichten.deBreakeven On The Horizon For Imugene Limited (ASX:IMU)August 8, 2024 | finance.yahoo.comImugene Limited (ILA.F)August 3, 2024 | finance.yahoo.comResection for Early Liver Cancer Tied to Improved SurvivalMay 16, 2024 | msn.comFrom high-tech cancer fighters to AI-wielding crime busters, these are some of the most innovative firms on the ASXMay 13, 2024 | msn.com‘Real hope’ for cancer cure as personal mRNA vaccine for melanoma trialledApril 26, 2024 | theguardian.comThose who invested in Imugene (ASX:IMU) five years ago are up 361%April 25, 2024 | finance.yahoo.comBroker says this ASX biotech stock could almost double in valueApril 23, 2024 | msn.com Get Imugene News Delivered to You Automatically Sign up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter. Email Address IMU Media Mentions By Week IMU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMU News Sentiment▼0.760.63▲Average Medical News Sentiment IMU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMU Articles This Week▼11▲IMU Articles Average Week Get Imugene News Delivered to You Automatically Sign up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Algernon Pharmaceuticals News Allstar Health Brands News American Premium Mining News Anew Medical News Arno Therapeutics News AstraZeneca News AVAX Technologies News AVVAA World Health Care Products News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:IMU) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Imugene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
